Project Full Title: Stratification of Obese Phenotypes to Optimize Future Obesity Therapy. Project acronym: SOPHIA SOPHIA is ... a European research project led by 29 International partners. The project aims to improve the risk assessment of complications of obesity and predict treatment response for people with obesity. Start date: 01 June 2020 Duration: 60 months Budget: € 16 Million Coordination: University College Dublin, Prof Carel le Roux Project Lead: Novo Nordisk A/S, Dr Marianne Ølholm Larsen Grønning This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition. About IMI The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu *Posts on this platform only reflect the views of the SOPHIA Consortium. read more